Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

FIGNL1 Inhibitors

Fidgetin-like 1 (FIGNL1) is a member of the AAA (ATPases Associated with diverse cellular Activities) ATPase family, characterized by its roles in various cellular processes including DNA repair, chromosome segregation, and the regulation of microtubule dynamics. As an enzyme, FIGNL1 contributes to the maintenance of genomic stability and proper cell division, showcasing its importance in cell cycle control. The precise molecular mechanisms through which FIGNL1 exerts its effects involve its ATPase activity, which powers the remodeling or disassembly of protein complexes, thus influencing the cellular machinery responsible for DNA replication, repair, and mitotic spindle formation. Through its involvement in these critical processes, FIGNL1 plays a vital role in ensuring that cells can accurately replicate their DNA and evenly distribute it between daughter cells during mitosis, highlighting its significance in cellular homeostasis and organismal health.

The inhibition of FIGNL1 could disrupt the aforementioned cellular processes, leading to impaired DNA repair mechanisms, erroneous chromosome segregation, and altered microtubule dynamics, all of which can contribute to genomic instability and the development of various pathologies, including cancer. Inhibition could occur through several mechanisms, such as the interaction with specific inhibitory proteins that block FIGNL1's ATPase activity, the alteration of its expression levels through regulatory pathways, or post-translational modifications that affect its function. Additionally, small molecule inhibitors could be designed to target the ATPase domain of FIGNL1, preventing ATP hydrolysis and thus its ability to remodel protein complexes essential for its role in the cell. Understanding these inhibitory mechanisms is crucial for unraveling the complex regulation of FIGNL1's activities and for the development of strategies aimed at diseases associated with its dysregulation. Exploring these pathways offers a glimpse into the intricate network of cellular maintenance and the delicate balance required for cellular and genomic integrity.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

AP 24534 (Ponatinib) inhibits FGFR1 by binding to its tyrosine kinase domain, blocking phosphorylation and downstream signaling, used in cancer therapy.

AZD4547

1035270-39-3sc-364421
sc-364421A
5 mg
10 mg
$198.00
$309.00
6
(1)

AZD4547 is a selective FGFR1-3 inhibitor, blocking their activation, signaling, and growth, making it a potential anticancer drug.

Erdafitinib

1346242-81-6sc-507388
10 mg
$138.00
(0)

Erdafitinib targets FGFR1-4 by blocking their tyrosine kinase activity, inhibiting tumor cell growth and proliferation in bladder cancer.

BGJ398

872511-34-7sc-364430
sc-364430A
sc-364430B
sc-364430C
5 mg
10 mg
50 mg
100 mg
$216.00
$252.00
$594.00
$1009.00
4
(1)

BGJ398 is an FGFR1-3 inhibitor that hinders receptor autophosphorylation, offering promise in the therapy of various cancers.

Debio-1347

1265229-25-1sc-507386
10 mg
$324.00
(0)

Debio-1347 disrupts FGFR1 signaling by targeting its kinase domain, offering potential benefits inadvanced solid tumors.

PD173074

219580-11-7sc-202610
sc-202610A
sc-202610B
1 mg
5 mg
50 mg
$47.00
$143.00
$680.00
16
(1)

PD173074 is a selective FGFR1 inhibitor that blocks its kinase activity, demonstrating potential in inhibiting cancer cell growth.